Wanessa Miranda-Silva1, Marco Aurélio Montezuma1, Bernar Monteiro Benites1, Julia Stephanie Bruno1, Felipe Paiva Fonseca2, Eduardo Rodrigues Fregnani3. 1. Department of Oral Medicine, Hospital Sírio-Libanês, Street Dona Adma Jafet 91-Bela Vista, São Paulo, SP, Brazil. 2. Department of Oral Surgery and Pathology, School of Dentistry, Federal University of Minas Gerais, Street Professor Moacir Gomes de Freitas 688, Belo Horizonte, Brazil. 3. Department of Oral Medicine, Hospital Sírio-Libanês, Street Dona Adma Jafet 91-Bela Vista, São Paulo, SP, Brazil. eduardofregnani@me.com.
Abstract
PURPOSE: To assess the current knowledge regarding medication-related osteonecrosis of the jaw (MRONJ); the adverse effects of anti-resorptive (AR) and anti-angiogenic (AA) drugs; strategies for MRONJ prevention and treatment; and perception of the dentist's role in assisting patients who use these drugs among physicians, dentists, and nurses. METHODS: Using questionnaires, the current knowledge of MRONJ was assessed among dentists, physicians, and nurses, who were divided into group I, which included specialties that directly assist cancer patients, and group II, which included other specialties. The questionnaires assessed the characteristics of the health professionals, training time, and specialties; their knowledge of AR and AA drugs; and their knowledge of MRONJ. RESULTS: A total of 1370 health professionals participated in the study, including 1032 dentists, 239 physicians, and 99 nurses. Among dentists and physicians, the training time (p = 0.036 and p < 0.001, respectively) and specialization in group I domains (p < 0.001 and p < 0.001, respectively) had a significant impact on MRONJ knowledge, while nurses showed no significant impact regardless of the training time and specialty. Less than 10% of the physicians and dentists could correlate the signs and symptoms of all stages of MRONJ. CONCLUSION: The findings indicated a notable lack of knowledge regarding MRONJ among dental surgeons and physicians, and especially among nurses. More experienced professionals and specialists in the areas that assist cancer patients usually have a greater understanding of the dentist's role in MRONJ prevention, diagnosis, treatment, and patient care and will introduce or are already using AR and AA drugs.
PURPOSE: To assess the current knowledge regarding medication-related osteonecrosis of the jaw (MRONJ); the adverse effects of anti-resorptive (AR) and anti-angiogenic (AA) drugs; strategies for MRONJ prevention and treatment; and perception of the dentist's role in assisting patients who use these drugs among physicians, dentists, and nurses. METHODS: Using questionnaires, the current knowledge of MRONJ was assessed among dentists, physicians, and nurses, who were divided into group I, which included specialties that directly assist cancerpatients, and group II, which included other specialties. The questionnaires assessed the characteristics of the health professionals, training time, and specialties; their knowledge of AR and AA drugs; and their knowledge of MRONJ. RESULTS: A total of 1370 health professionals participated in the study, including 1032 dentists, 239 physicians, and 99 nurses. Among dentists and physicians, the training time (p = 0.036 and p < 0.001, respectively) and specialization in group I domains (p < 0.001 and p < 0.001, respectively) had a significant impact on MRONJ knowledge, while nurses showed no significant impact regardless of the training time and specialty. Less than 10% of the physicians and dentists could correlate the signs and symptoms of all stages of MRONJ. CONCLUSION: The findings indicated a notable lack of knowledge regarding MRONJ among dental surgeons and physicians, and especially among nurses. More experienced professionals and specialists in the areas that assist cancerpatients usually have a greater understanding of the dentist's role in MRONJ prevention, diagnosis, treatment, and patient care and will introduce or are already using AR and AA drugs.
Entities:
Keywords:
Bisphosphonate-related osteonecrosis of the jaw; Health professionals; Medication-related osteonecrosis of the jaw; Osteonecrosis of the jaw; Questionnaires
Authors: Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez Journal: Support Care Cancer Date: 2015-03-11 Impact factor: 3.603
Authors: B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski Journal: Br J Cancer Date: 2012-11-06 Impact factor: 7.640
Authors: Emanuel Bruckmoser; Miriam Palaoro; Lukas Latzko; Dagmar Schnabl; Sabrina B Neururer; Johannes Laimer Journal: Int J Environ Res Public Health Date: 2021-04-22 Impact factor: 3.390